Royalty Pharma plc (RPRX)
Sector: Healthcare
Industry: Pharmaceutical Preparations
Country: United States
Exchange: NASDAQ
Market cap: $33.89B
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Latest financial period: June 30, 2026
Filed with the SEC: August 5, 2026
Estimated earnings date: November 4, 2026
Not currently ranked. Cannot calculate: FCF yield
Profit Not currently ranked
| | Jun 26 | Mar 26 | Dec 25 | Sep 25 |
|---|
| ROIC | 9.6% | 10.1% | 8.6% | 9.2% |
Growth Not currently ranked
Payout Not currently ranked
Safety Not currently ranked
Price Not currently ranked
